Effect of Bempedoic Acid vs Placebo Added to Statins on LDL-C in Patients at High Risk for CVD

This randomized clinical trial compares the efficacy of bempedoic acid, an experimental drug that inhibits an enzyme upstream of HMG-CoA reductase, vs placebo for lowering levels of low-density lipoprotein cholesterol (LDL-C) in patients at high cardiovascular risk with ongoing hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
Source: JAMA - Category: General Medicine Source Type: research

Related Links:

Have rates of statin use for secondary prevention improved over the last decade? Do disparities still exist by gender or racial/ethnic groups?Journal of the American Board of Family Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
This study suggests that for most, managing CAD with medications alone (the conservative approach) is as safe and effective as the more invasive strategy of cardiac catheterization and opening of the blocked artery. Findings of the ISCHEMIA trial ISCHEMIA followed over 5,000 patients with significant narrowing in one or more coronary arteries. Half of the patients were randomly selected to receive conservative treatment with optimal medical therapy (OMT) and lifestyle changes to treat risk factors such as high blood pressure and high cholesterol. The other half were given OMT and also sent for cardiac catheterization (thre...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Source Type: blogs
(Oxford University Press USA) A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use. Researchers concluded that aspirin no longer provides a net benefit as primary prevention for cardiovascular disease and cancer.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
The impact of body mass index (BMI) on cardiovascular outcomes among patients receiving intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy is uncertain. We performed meta-analysis of 29 randomized controlled trials using PubMed, Embase and CENTRAL through April 2019. Therapies were grouped as more intensive LDL-C lowering therapy (statins, ezetimibe  + statin or PCSK9 inhibitors) and less intensive LDL-C lowering therapy (less potent active control or placebo). Random effects meta-regressions and meta-analyses were performed to evaluate association of BMI with cardiovascular endpoints.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
The objective of the work was to develop the marine-derived polysaccharides attenuating 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), and as prospective natural anti-dyslipidemic leads. Physical and chromatographic purification methods were used to isolate the polygalactofucan from the marine macroalgaSargassum wightii andβ-(2-deoxy)-amino-substituted glucopyrananan from a marine crustacean. Glycosidic linkage analysis by the process of methylation was used for structural elucidation of the polygalactofucan, and the methylated and partially methylated alditol acetates were characterized using extensive spectroscop...
Source: Medicinal Chemistry Research - Category: Chemistry Source Type: research
Publication date: Available online 7 December 2019Source: Revista Española de Cardiología (English Edition)Author(s): Carlos Escobar, Manuel Anguita, Vicente Arrarte, Vivencio Barrios, Ángel Cequier, Juan Cosín-Sales, Isabel Egocheaga, Esteban López de Sa, Luis Masana, Vicente Pallarés, Leopoldo Pérez de Isla, Xavier Pintó, José Ramón González Juanatey, José Luis ZamoranoAbstractThe current control of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease is very low and this is associated with an inc...
Source: Revista Espanola de Cardiologia - Category: Cardiology Source Type: research
Publication date: Available online 7 December 2019Source: American Heart JournalAuthor(s): Sarah T. Ahmed, Dhruv Mahtta, Hasan Rehman, Julia Akeroyd, Mahmoud Al Rifai, Fatima Rodriguez, Hani Jneid, Khurram Nasir, Zainab Samad, Mahboob Alam, Laura A. Petersen, Salim S. ViraniBackgroundStatin use remains suboptimal in patients with atherosclerotic cardiovascular disease (ASCVD). We assessed if the frequency of visits with primary care providers (PCPs) is associated with higher use of evidence-based statin prescriptions and adherence among patients with ASCVD.MethodsWe identified patients with ASCVD aged ≥18 years rec...
Source: American Heart Journal - Category: Cardiology Source Type: research
CONCLUSIONS: This study did not support an association between statin use and diagnostic conversion but suggested a possible association between statin use and cognitive change in EMCI. Additional randomized clinical trials of statins may be warranted in the prodromal EMCI stage of AD. PMID: 31806426 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
ConclusionSignificant moderate association between CRP and several blood tests was evaluated in apparently healthy population. This information should be used for further studies of the relationship between inflammation and biological processes.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Authors: Sevim E, Willis R, Erkan D Abstract Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional APS treatment focuses on antithrombotic strategies, which are usually ineffective for the microvascular and nonthrombotic manifestations of aPL. Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition ...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Clinical Trials | General Medicine | Heart | Statin Therapy